SciELO - Scientific Electronic Library Online

 
vol.146 número12Sintomatologia depresiva y control metabólico en pacientes ambulatorios portadores de diabetes mellitus tipo 2Fuerza de agarre isométrica máxima en relación a la edad, sexo y dominancia de mano índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Revista médica de Chile

versión impresa ISSN 0034-9887

Resumen

ARIAS-FLOREZ, Juan Sebastián et al. Conventional serum tumor markers in liver cancer. Retrospective analysis of 118 patients. Rev. méd. Chile [online]. 2018, vol.146, n.12, pp.1422-1428. ISSN 0034-9887.  http://dx.doi.org/10.4067/s0034-98872018001201422.

Background:

Conventional serum tumor markers (CSTM) are widely used for monitoring patients with cancer. However, their usefulness as a diagnostic tool is controversial in primary or metastatic liver cancer (PMLC).

Aim:

To evaluate the diagnostic performance of the most commonly requested CSTM in the diagnostic approach of PMLC.

Material and Methods:

Review of medical records of patients aged over 18 years with a liver biopsy, attended from 2005 to 2017 in a tertiary hospital and a regional cancer center in Colombia. The results of liver biopsies were compared with tumor markers such as carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), CA 19-9, CA 125 and prostate specific antigen (PSA) using a receiver operating characteristic (ROC) curve analysis.

Results:

We reviewed 2063 medical records and retrieved 118 eligible patients (59 cases and 59 controls, 70% males). Thirty percent had obstructive jaundice. There was heterogeneity in the amount of tumor markers requested according to medical criteria. Only CA 19-9 showed discriminative capacity (> 17.6 U/m), with a cut-off point lower than that reported in the literature and a sensitivity of 69.5%, specificity of 91.6%, a positive likelihood ratio (LR) of 8.32, and a negative LR of 0.33.

Conclusions:

Except for CA 19-9, tumor markers were not useful for the initial diagnostic approach in patients with suspected primary or metastatic malignant liver tumors.

Palabras clave : Biomarkers, Tumor; Liver Neoplasms; Mass Screening.

        · texto en Español     · Español ( pdf )